---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Sano Genetics

🌎 sanogenetics.com

Sano Genetics is a biotechnology research company based in Cambridge, England, focused on accelerating the transition to precision medicine. The company offers an end-to-end precision medicine platform that integrates genetic testing, recruitment, and long-term patient engagement, streamlining clinical operations and enhancing the efficiency of clinical trials.

---

Sano Genetics - Latest News and Updates

• Sano Genetics is supporting a research program with Prevail Therapeutics to provide free at-home genetic testing and counseling for frontotemporal dementia (FTD).
• Sano Genetics has launched a new partnership with 20/20 Onsite and Clinical Enrollment to improve participant selection for inherited retinal disease trials, announced during the American Academy of Ophthalmology event in Chicago.
• Sano Genetics has been named in Bloomberg UK's Startups to Watch 2024 and announced a new partnership to enhance specialist eye care and research in the USA.
• Sano Genetics has been named one of Bloomberg's Startups to Watch 2024, highlighting their innovation and diversity.
• Paul Wicks, Vice President of Neuroscience at Sano Genetics, emphasized the importance of UK participants benefiting from promising drug research.

• Sano Genetics is hosting the first-ever Genetics Podcast Meetup on November 7th in Denver.
• Sano Genetics won silver in the Global Good Awards for their Genetics of Long Covid study and analysis with PrecisionLife, identifying 42 genes for potential drug discovery.
• Sano Genetics released a whitepaper on global market expansion and the future of precision medicine.
• Sano Genetics' Paul Wicks co-authored a new paper in the Journal of Medical Internet Research on embedding DEI in digital mental health interventions.
• Paul Wicks, Vice President of Neuroscience at Sano Genetics, co-authored a new paper on DEI in digital mental health interventions with Woebot Health, published in the Journal of Medical Internet Research.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.